Reverse DCF
What growth does the market imply for SUNPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
12.5% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹1,806
Historical Growth
4.1%
FCF Yield
2.03%
Price / FCF
49.2x
Plain English
To justify today's price of ₹1806.00, SUNPHARMA.NS needs to grow its free cash flow at 12.5% per year for the next 10 years. That is 8.4% faster than its historical growth rate of 4.1%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 4.1% | ₹902 | -50.1% |
| Half implied | 6.3% | ₹1,074 | -40.5% |
| GDP rate | 10.0% | ₹1,462 | -19.0% |
| Implied | 12.5% | ₹1,806 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 4.1% growth, the model values SUNPHARMA at ₹902, below today's ₹1,806.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.